Integrated analysis of multi-omics data to establish clinical and molecular profiles predictive of the development of recurrent uveitis in patients with Ankylosing Spondylitis

Welcome to MOMPRUAA

MOMPRUAA is a national, multicenter project that aims to increase the predictive capacity to anticipate the risk of recurrent uveitis (acute anterior uveitis UAA) in patients with ankylosing spondylitis (AS).

A multiomic profile will be performed that will include the analysis of the main plasma biomarkers involved in the development and severity of uveitis and AD, and a metagenomics and metabolomics analysis to discern the involvement of the microbiome as an environmental inducer in the development of the process Bioinformatics tools will be used to establish predictive models machine learning.


Health R+D+I projects of the Carlos III Health Institute 2022. File No. PI22/01775

Development of MOMPRUAA

Main cohort

  • 35 patients with HLA-B27 positive AD with recurrent UAA without biological treatment (TB)
  • 35 control cohort patients with HLA-B27 positive EA without uveitis and without TB, matched by age, gender and time of disease evolution

exploratory cohort

  • 10 HL-AB27-negative EA patients with recurrent UAA without TB
  • 10 HLA-B27 positive EA patients with TB with relapsed UAA
  • 10 HLA-B27 positive EA patients with TB without UAA

Samples to be collected within a maximum of 4 weeks after the episode of UAA

  • Faeces: 2 jars, red lid jar and brown lid jar with DNA preservation
  • Blood: whole blood, serum and plasma.

Exclusion criteria

  • Patients under 18 years of age
  • Patients who do not sign informed consent
  • Patients with other chronic diseases that may affect the outcome of the study, such as immune-mediated inflammatory diseases and/or autoimmune diseases, obesity (BMI >30) diabetes, history of neoproliferative disease in the last 5 years, severe chronic kidney disease, disease severe mental and/or cognitive impairment
  • Patients on biological therapy (TNFi, IL17/Il23i, JAKi) (for the main cohort)
  • Patients who have received treatments or interventions that can modify the microbiome: antibiotic or probiotic treatment in the previous 3 months, having undergone a colostomy, having received preparation for colonoscopy in the previous six months, and having undergone surgeries extensive the previous month.

Participating centers

  • Hospital Universitari Parc Taulí (Sabadell)
  • Hospital Universitari de Vall D’Hebron (Barcelona)
  • Hospital Universitari Germans Trias i Pujol (Barcelona)
  • Hospital Universitari de la Santa Creu i Sant Pau (Barcelona)
  • Hospital Universitario Reina Sofía (Cordoba)
  • Xarxa Assistencial Universitària de Manresa (Barcelona)
  • Hospital Universitario de Basurto (Bilbao)
  • Hospital General de Málaga (Málaga)
Privacy preferences

When you visit our website, your browser may store information about specific services, usually in the form of cookies. Here you can change your privacy preferences. Please note that blocking certain types of cookies may affect your experience on our website and the services we offer.

Enable / disable Google Analytics tracking code
Enable / disable Google Fonts
Turn Google Maps on / off
Enable / disable embedded videos
This website uses cookies, mainly from third party services. You can edit your privacy preferences and / or accept the use of cookies.